Internal Ribosome Entry Site Dramatically Reduces Transgene Expression in Hematopoietic Cells in a Position-Dependent Manner

• Main Authors: Qingyun Zheng, Xueyan Zhang, Hua Yang, Jinyan Xie, Yilin Xie, Jinzhong Chen, Chenghui Yu, Chen Zhong
• Format: Article
• Language: English
• Published: MDPI AG 2019-10-01
• Series: Viruses
• Subjects: internal ribosome entry site (ires); recombinant adeno-associated virus vector; hematopoietic cells; bicistronic transgene; gene therapy
• Online Access: https://www.mdpi.com/1999-4915/11/10/920

Bicistronic transgene expression mediated by internal ribosome entry site (IRES) elements has been widely used. It co-expresses heterologous transgene products from a message RNA driven by a single promoter. Hematologic gene delivery is a promising treatment for both inherited and acquired diseases. A combined strategy was recently documented for potential genome editing in hematopoietic cells. A transduction efficiency exceeding ~90% can be achieved by capsid-optimized recombinant adeno-associated virus serotype 6 (rAAV6) vectors. In this study, to deliver an encephalomyocarditis virus (EMCV) IRES-containing rAAV6 genome into hematopoietic cells, we observed that EMCV IRES almost completely shut down the transgene expression during the process of mRNA−protein transition. In addition, position-dependent behavior was observed, in which only the EMCV IRES element located between a promoter and the transgenes had an inhibitory effect. Although further studies are warranted to evaluate the involvement of cellular translation machinery, our results propose the use of specific IRES elements or an alternative strategy, such as the 2A system, to achieve bicistronic transgene expression in hematopoietic cells.